SAN DIEGO, Sept. 29, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced participation in the upcoming 21(st) International Annual Congress of the World Muscle Society (WMS) being held October 4-8, 2016 in Granada, Spain.

http://photos.prnewswire.com/prnvar/20120809/MM55538LOGO

Poster Presentation: Thursday Oct. 6, 2016 from 15:00-16:30 (CEST) 


    --  Title: A Randomized, Double-blinded, Placebo-controlled, Multiple
        Ascending Dose Study to Evaluate the Safety, Tolerability,
        Pharmacokinetics, Immunogenicity, and Biological Activity of ATYR1940
        (Resolaris(TM)) in Adult Patients with Facioscapulohumeral Muscular
        Dystrophy.
    --  Author and Presenter: Dr. Ari Gershman, Senior Medical Director, aTyr
        Pharma
    --  Supporting Authors: Chiang K, Do M-H, Abbink E, Harbers V, Audebert C,
        Campana-Salort E, Monforte M, Iyadurai S, Carey L, Heskamp L, Kan HE,
        Heerschap A, Kissel J, Ricci E, Attarian S, Blackburn K, Mendlein JD,
        and Ashlock MA.

About FSHD

Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic myopathy affecting an estimated 19,000 people in the United States for which there are no approved treatments. The primary clinical phenotype of FSHD is debilitating skeletal muscle deterioration and weakness. The symptoms of FSHD often appear early in the face, shoulder blades, upper arms, lower legs and trunk, and can affect certain muscles while adjacent muscles remain healthy. In addition to muscle weakness, FSHD patients often experience debilitating fatigue and chronic pain. The disease is typically diagnosed by the presence of a characteristic pattern of muscle weakness and other clinical symptoms, as well as through genetic testing. Early onset FSHD occurs in individuals who experience symptoms of progressive muscle involvement as juveniles, and some of these patients suffer from a particularly severe form of the disease. To learn more about FSHD, please visit www.fshsociety.org.

About Resolaris(TM)

aTyr Pharma is developing Resolaris as a potential first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Resolaris is derived from a naturally occurring protein released in vitro by human skeletal muscle cells. aTyr believes Resolaris has the potential to provide therapeutic benefit to patients with rare myopathies with an immune component characterized by excessive immune cell involvement.

About aTyr Pharma

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris(TM), is a potential first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Resolaris is currently in a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (FSHD); a Phase 1b/2 trial in adult patients with limb-girdle muscular dystrophy 2B (LGMD2B or dysferlinopathies) or FSHD; and a Phase 1b/2 trial in patients with an early onset form of FSHD. To protect this pipeline, aTyr has built an intellectual property estate comprising over 80 issued or allowed patents and over 230 pending patent applications that are owned or exclusively licensed by aTyr, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.

Contact:
Mark Johnson
Sr. Director, Investor Relations
mjohnson@atyrpharma.com
858-223-1163

Logo - http://photos.prnewswire.com/prnh/20120809/MM55538LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atyr-pharma-announces-presentation-at-the-21st-international-annual-congress-of-the-world-muscle-society-300336251.html

SOURCE aTyr Pharma, Inc.